替诺福韦与恩替卡韦在慢性乙肝患者中的应用效果分析  

Analysis of the application effect of tenofovir and entecavir in patients with chronic hepatitis B

作　　者：张晶 ZHANG Jing(Benxi Sixth People’s Hospital,Benxi 117000,China)

机构地区：[1]辽宁省本溪市第六人民医院,117000

出　　处：《中国实用医药》2021年第32期128-130,共3页China Practical Medicine

摘　　要：目的研究恩替卡韦与替诺福韦治疗慢性乙型肝炎(乙肝)的临床效果。方法70例慢性乙肝患者,以随机抽取的方式分为A组和B组,每组35例。A组患者给予恩替卡韦治疗,B组患者给予替诺福韦治疗。对比两组患者治疗前后乙肝病毒脱氧核糖核酸(HBV DNA)水平及治疗6个月后HBV DNA转阴率、谷丙转氨酶(ALT)复常率、乙肝病毒e抗原(HBeAg)转阴率。结果治疗3、6个月后,B组患者的HBV DNA水平分别为(4.23±0.44)×10^(4) IU/ml、(1.01±0.26)×10^(4) IU/ml,均显著低于A组的(5.12±0.57)×10^(4) IU/ml、(1.57±0.34)×10^(4) IU/ml,差异具有统计学意义(P<0.05)。B组患者的HBV DNA转阴率94.29%(33/35)、ALT复常率88.57%(31/35)、HBeAg转阴率91.43%(32/35)均高于A组的74.29%(26/35)、68.57%(24/35)、65.71%(23/35),差异具有统计学意义(χ^(2)=5.2851、4.1576、6.8727,P=0.0215、0.0414、0.0088<0.05)。结论相较于恩替卡韦,替诺福韦用于慢性乙肝治疗具有更强的抗病毒能力,HBV DNA转阴率、ALT复常率以及HBeAg转阴率均明显更高,值得临床推广。Objective To study the clinical effect of tenofovir and entecavir in patients with chronic hepatitis B.Methods A total of 70 patients with chronic hepatitis B were randomly divided into group A and group B,with 35 cases in each group.Patients in group A were treated with entecavir,and patients in group B were treated with tenofovir.Both groups were compared in terms of hepatitis B virus deoxyribonucleic acid(HBV DNA)before and after treatment,and the negative-conversion rate of HBV DNA,alanine aminotransferase(ALT)normalization rate,and negative-conversion rate of hepatitis B e antigen(HBeAg)after 6 months of treatment.Results After 3 and 6 months of treatment,the HBV DNA levels of patients in group B were(4.23±0.44)×10^(4) IU/ml and(1.01±0.26)×10^(4) IU/ml,which were significantly lower than(5.12±0.57)×10^(4) IU/ml and(1.57±0.34)×10^(4) IU/ml in group A,and the difference was statistically significant(P<0.05).The negativeconversion rate of HBV DNA 94.29%(33/35),the normalization rate of ALT 88.57%(31/35),and the negativeconversion rate of HBeAg 91.43%(32/35)in group B were higher than 74.29%(26/35),68.57%(24/35)and 65.71%(23/35)in group A,and the difference was statistically significant(χ^(2)=5.2851,4.1576,6.8727;P=0.0215,0.0414,0.0088<0.05).Conclusion Compared with entecavir,tenofovir has stronger antiviral ability in the treatment of chronic hepatitis B,and the negative-conversion rate of HBV DNA,ALT normalization rate and negative-conversion rate of HBeAg are significantly higher,which is worthy of clinical promotion.

关 键 词：恩替卡韦 替诺福韦 慢性乙型肝炎 乙型肝炎病毒脱氧核糖核酸 谷丙转氨酶 乙型肝炎病毒E抗原 

分 类 号：R512.62[医药卫生—内科学]